Merck (MRK) Acquisition presentation summary
Event summary combining transcript, slides, and related documents.
Acquisition presentation summary
12 Nov, 2026Transaction and strategic rationale
All-cash proposal of $20 per Silence Therapeutics ADS, representing €0.9bn enterprise value; closing expected in Q1 2027, subject to relevant approvals.
Expected IRR exceeds WACC and supports Healthcare’s long-term mid-single-digit growth ambition.
Transaction supports rare-disease growth, replenishes Healthcare’s mid-stage pipeline and advances the Global Specialty Innovator strategy.
Strengthens oligonucleotide capabilities, with potential expansion in hematology-oncology and adjacent targeted specialty and rare diseases.
Divesiran opportunity and clinical evidence
Silence Therapeutics is a clinical-stage biotech focused on siRNA therapies; lead asset divesiran is pre-Phase III with best-in-class potential in polycythemia vera (PV), a rare chronic blood cancer.
PV has ~100k addressable patients in the US by company estimate; unmet need includes phlebotomy-free treatment and superior, durable hematocrit control.
Divesiran targets TMPRSS6 via GalNAc-conjugated siRNA, enhancing the hepcidin pathway; subcutaneous dosing supports Q12W administration.
Phase II primary endpoint met: 88% clinical response with divesiran vs 19% with placebo during weeks 18–36 (p<0.0001); placebo-adjusted response rate 69%.
Mean phlebotomies during weeks 0–36 were 0.2 with divesiran vs 2.1 with placebo (p<0.0001); results also showed improved hematocrit control, iron markers and reported quality of life.
Divesiran was generally well tolerated, with no new safety findings; Phase III initiation is supported for H1 2027, with potential upside in other iron-overload indications.
Latest events from Merck
- AI-linked semiconductor demand and Rare Diseases growth supported Q3 as FY26 guidance rose.MRK
Q3 2026 (Media) - Raised FY26 guidance amid Q3 growth, CDMO impairment and Mavenclad pressure.MRK
Q3 2026 - Growth fueled by innovation, strategic M&A, and sustainability across all business sectors.MRK
Corporate presentation - Upgraded 2026 guidance as Life Science and Electronics drive growth, with margin expansion.MRK
Q2 2026 - Strong early oncology pipeline progress with promising DDR and ADC assets advancing to clinic.MRK
Investor Update - Q3 2025 delivered robust organic growth, higher margins, and a positive outlook despite FX risks.MRK
Q3 2025 - Growth and margin expansion driven by rare diseases, semiconductor solutions, and innovation.MRK
CMD 2025 - Growth, innovation, and sustainability drive upgraded ambitions and operational excellence.MRK
CMD 2024 - Q1 2025 delivered solid growth and margin gains, with guidance reflecting macro headwinds.MRK
Q1 2025